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ABSTRACT 
Objective: (1) To measure the levels of matemal plasma 
corticotrophin-releasing hormone (CRH) in pregnancies complicated by 
preterm labour and compare with those of normal pregnancies at 
matched gestation in a cohort of Chinese women; (2) to compare the 
matemal plasma alpha-fetoprotein (AFP) levels between pregnancies 
complicated by preterm delivery and normal pregnancies at matched 
gestation in same cohort. 
Study Design : A prospective case-controUed study was conducted on 
pregnant Chinese women in the Prince of Wales Hospital. Recruitment 
was made after counseUing and informed consent. Thirty pregnant 
Chinese women who had spontaneous preterm delivery between 24-36 
weeks' gestation were recruited in the study group. The control group 
consisted of 30 healthy pregnant Chinese women, matched with gestation 
at blood sampling, who subsequently delivered at term. 
Main Outcome Measures : Plasma levels of CRH as determined 
by radioimmunoassay and plasma levels of AFP as determined by 
Microparticle Enzyme Lmnunoassy. 
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Results : Matemal plasma CRH concentrations in preterm labour rose 
from 261.1 pmoVmL at 26 weeks to 1485.65 pmoVmL at 36 weeks in 
preterm group and from 32.24 pmoymL at 26 weeks to 779.98 pmoLtol 
at 36 weeks in control group. The levels of CRH in preterm group 
were significantly higher than those of the control group (p=0.008). The 
levels of AFP in preterm group slightly declined from 215.83 pg/ml at 
26 weeks to 172.47 pg/ml at 36 weeks, but in control group the levels 
rose slightly from 193.29 pg/ml at 26 weeks to 217.73 pgytal at 36 
weeks. There were however no statisticaUy significant correlation between 
AFP levels and gestational age of sampling, to addition, there was no 
significant difference in the levels of AFP between the preterm group 
and the control group (P=0.336). 
Conclusion : (1) The levels of matemal plasma CRH in pregnancies 
complicated by preterm labour are higher than those of normal 
pregnancies. This is in agreement with the observation previously 
reported in the Caucacian population. Corticotrophin-releasing hormone 
may serve as marker for predicting the likelihood of preterm partuition. 
(2) The matemal plasma AFP levels in preterm group are not shown to 
be different from the control group. The failure of finding a relationship 
with preterm labour refutes the suggestion that matemal serum alpha-
fetoprotein (AFP) can be used as a biochemical marker for the 
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CHAPTER I 
INTRODUCTION AND OBJECTIVES 
Preterm birth, defined as delivery before 37 completed weeks' 
gestation, occurs in 7% of the local Hong Kong Chinese population 
OLeung et al 1998). It remains the leading cause of perinatal mortality 
and morbidity in developed countries ^V[cLean et al 1993). Although 
sophisticated neonatal intervention has brought along a reduction in 
perinatal mortality, the morbidity resulted from premature birth remains a 
huge financial burden to the society, the hospital and the parents. The 
psychological implications to the parents are also enormous. Up till 
today, there is no effective means of predicting pregnant women who 
are likely to deliver preterm. Li addition, the exact mechanism of how 
preterm labour is triggered remains poorly understood. 
Corticotrophin-releasing hormone (CRH) is a 41 amino acid 
peptide which is released from the hypothalamus. The hypothalamic 
CRH is released in response to stress and is a key regulator of 
pituitary-adrenal fimction (Orth 1992). The plasma levels of CRH are 
low or undetectable in normal non-pregnant women 0-inton et al 1987). 
The levels are high in normal pregnant women in the second and the 
third trimesters (Goland et al 1988, McLean et al 1995). The CRH 
which is detected in matemal plasma during human pregnancy is of 
placental in origin (Perkins and Linton 1995). It is primarily produced 
within the syncytiotrophoblast layer of the chorionic villi during 
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pregnancy (Riley et al 1991). The syncytiotrophoblast is bathed in 
matemal blood, providing a direct route for placental CRH to access the 
matemal circulation in significant amounts. The coding region for the 
placental CRH gene (Robinson et al 1989) has been shown to be 
identical to that of the hypothalamus (Shibahara et al 1983) and peptide 
produced from both sites has been shown to be functionally equivalent 
(Goland et al 1988). 
Li human pregnancy, the matemal plasma CRH levels are very 
low before 18 gestational weeks. It increases in the second trimesters in 
normal pregnancy, and rises dramatically in the third trimester and 
peaking at delivery before declining rapidly after delivery of the 
placenta (Campbell et al 1988; Perkins & Linton 1995, McLean et al 
1995). 
The exact ftmction of this placental CRH is still unclear, but the 
plasma CRH level is significantly elevated in a variety of pregnancy 
complications including preterm labour (Wolfe et al 1988 ； Warren et al 
1992 ； McLean et al 1995),preeclampsia (Wolfe et al 1988 ； Perkins et al 
1995) and intrauterine growth retardation (Goland et al 1993). The 
association with preterm birth is particularly strong (Warren et al 1992). 
Patients having preterm delivery may show elevated CRH levels weeks 
before the onset of symptoms and signs of preterm labour (Wolfe et al 
1998, McLean et al 1995). All these observations on CRH were 
conducted in westem population. Different ethnic groups may have 
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different aetiologies accounting for preterm delivery. It is therefore 
important to validate the findings in the local population. 
Alpha-fetoprotein (AFP) is a specific glycoprotein which is 
synthesized initially in the fetal yolk sac and subsequently in the fetal 
liver (Gitlin 1975). The concentration of AFP in fetal serum increases 
rapidly to a peak level of approximately 30g/L at 12 to 13 weeks of 
gestation (Gitlin and Boseman 1966) and gradually decreases towards 
term to a concentration of approximately 50 mgyTL in cord blood. The 
amniotic fluid alpha-fetoprotein reaches its peak concentration of around 
20mg/L during 13 gestational weeks and is approximately 150 to 200 
times less than that of fetal serum concentration (Crandall et al 1987). 
The concentration of alpha-fetoprotein in matemal serum increases until 
28-32 weeks of gestation and declines slightly to term. 
During second-trimester pregnancy, unexplained matemal serum 
AFP elevations are associated with increased risks of preterm delivery 
QVKlunsky et al 1989). Some studies also reported that both fetal 
growth retardation and preterm delivery are associated with elevated 
levels (Corry et al 1984). 
As the measurement of mid-trimester AFP levels can be predictive 
of spontaneous preterm delivery, the AFP levels in the third trimester 
may also be different between those delivering preterm and those who 
deliver at term. 
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There are two null hypotheses of this thesis: 
Hypothesis 1 
The matemal plasma CRH levels are higher in pregnancies complicated 
by spontaneous preterm delivery than those of normal pregnancies in 
our local Chinese population. 
Hypothesis 2 
The third trimester matemal plasma AFP levels in pregnancies 
complicated by preterm delivery are higher than those of normal 




IlA: Cortcotrophin-releasing Hormone 
Cortiocotrophin-releasing hormone was originally purified and 
sequenced from ovine hypothalamic tissue (Vale et al 1981) and was 
later found in rat OBuckingham and Hodges 1977) and human 
hypothalamus (Ackland et al 1986). Corticotrophin-releasing hormone 
production in humans is not limited tothe hypothalamus, but has been 
localised in the extra-hypothalamic central nervous system, lumber 
cerebrospinal fluid, amniotic fluids and the placenta (Orth 1992). 
EA.1. Structure of Corticotrophin-releasing hormone 
Corticotrophin-releasing hormone is a 41 amino acid peptide 
synthesised from an inactive precursor of 190 amino acid. It is found 
in positions 148-188 of this precusor. The sequence of human CRH 
was found to be identical to that of the rat (Fig.l), but different from 
ovine CRH by seven amino acids (Vale et al 1983). The CRH molecule 
is hydrophobic and the carboxyl terminus of the CRH molecule is 
critical for its biological activity. The minimal amino acid sequence 
required for full CRH activity is the 15-41 fragment (Vale et al 1981). 
The CRH peptide is susceptible to oxidation due to its methionine 
residue and the oxidised form of CRH only possesses 1-10% of the 






Fig. 1 :Amino acid sequence of human corticotrophin-releasing hormone. 
Peptide hormones are made of individual amino acids which are linked 
by peptide bonds to form polypeptide chains. Underlined is (i) the 
carboxyl terminal which is critical for CRH biological activity and (ii) 
are the methionine residues which are readily oxidised to make the 
CRH peptide unstable. Amino acids 15-41 are needed for CRH to 
have biological activity. 
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IL\.2.Corticotrophin-releasing hormone and normal physiology 
II.A.2.a. Hypothalamic-Pituitary-Adrenal (HPA) axis 
Corticotrophin-releasing hormone is produced from the 
paraventricular nuclei of the hypothalamus. Li 1948, Harris reported the 
relationship of the central nervous system and the adenohypophysial 
endocrine system by finding the hypothalamic factors to be released into 
the hypothalamic portal vasculature (Harris 1948). The axons which 
arise from the cell bodies of paraventricular nuclei end in the median 
eminence where CRH is released into the portal hypophyseal vessels 
which link to the capillary bed of the anterior pituitary (also called 
adenohypophysis or pars distalis). Jn several minutes, CRH is 
enzymatically degraded and released to the systemic circulation. 
However, due to the direct link between the hypothalamus and the 
anterior pituitary, only small concentration of CRH from the 
hypothalamus is sufficient to elicit a response in the anterior pituitary. 
Corticotrophin-releasing hormone stimulates the specific hormone 
producing cell (corticotropes) of the anterior pituitary to release ACTH 
and B-endorphin ^S-EP). These two peptide hormones have the same 
polypeptide precursor. Then ACTH acts on the adrenal cortex to 
produce the glucocorticoids which are cortisol, cortisone and 
corticosterone . Glucocorticoids promote gluconeogenesis in the liver by 
increasing enzymes, and also elevate the mobilization of glucose from 
non-carbohydrate sources to increase blood glucose and reduce uptake of 
amnio acids into muscle. The mobilization of fatty acids from adipose 
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tissue to increase blood glucose is another way of non-carbohydrate 
sources for gluconegenesis. During stress , the elevated blood glucose 
provides energy for the muscle and nervous tissue. These 
glucocorticoids have a negative feedback loop at the level of the 
anterior pituitary to control ACTH release and at the level of the 
hypothalamus to regulate CRH release. 
ILA.2.b. Role of Hypothalamic-Pituitary-Adrenal axis 
The endocrine response to stress is mediated by a pathway of 
signals between three organs which is caUed the Hypothalamic-Pituitary-
Adrenal OHDPA) axis. It plays a critical role in the neuroendocrine 
response to environmental stressful stimuli such as pain and trauma 
(^imier and Plotsky 1986). The HPA and sympathetic nervous system 
mediate the behavioural, cardiovascular and metabolic changes to allow 




Li pregnancy, CRH is also secreted from the syncytiotrophoblast 
layer of the chorionic villi (Warren and Siverman 1995). The source of 
this placental CRH has been supported by the disappearance of 
measurable concentrations within 24 hours after delivery, and CRH are 
low or not measurable in non-pregnant women. Another evidence is that 
a CRH messenger ribonucleic acid is present in the placenta (Frim et al 
1987). This CRH messenger ribonucleic acid is localized in the 
syncytiotrophoblast and is gestationally regulated. It is found that CRH 
messenger ribonucleic acid increased as gestational age advances. This 
rise of matemal CRH in pregnancy is accompanied by the rise of 
placental CRH messenger ribonucleic acid. 
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ILA.3.b. Physiology 
Evidence from in vitro and in vivo studies suggests that placental 
CRH is biologically active and stimulates the fetal pituitary to release 
ACTH during pregnancy. Then ACTH acts on the fetal adrenal cortex to 
stimulate production of glucocorticoids. Ln vitro, the secretion of the 
placental CRH is stimulated by glucocorticoids, suggesting a positive 
feedback between the fetal pituitary-adrenal axis and placental CRH 
^lobinson et al 1988). 
A large amount of CRH is secreted by the placenta into both the 
matemal and fetal circulation. The matemal plasma CRH levels increase 
as the gestational age of the pregnancy advances. This rise is 
accompanied by sequential increases in ACTH and free cortisol 
concentrations (Robin et al 1994), which implies that placental CRH 
may modulate both the matemal and fetal hypothalamic-pituitary-adrenal 
axis during gestation. This is supported by the finding of a higher CRH 
concentration in the umbilical vein than in the umbilical artery and by 
the disappearance of this peptide from matemal plasma after delivery. 
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II.A.3.c. Normal pregnancy 
The matemal plasma CRH is undetectable in women from the 
&st trimester to mid-trimester of pregnancy, but it increases throughout 
the second and early third trimester, then rise exponentially from 35 
weeks to term (Campbell et al 1987). This shows a temporal positive 
correlation between the CRH and gestational age. The level of CRH 
declines rapidly after delivery (Sasaki et al 1984; Campbell et al 1987). 
The CRH-binding protein (CRH-BP) can inhibit the bioactivity of 
CRH through the binding to the hormone in an equimolar ratio and 
prevents its recognition at the CRH receptor in the matemal circulation 
(Potter et al 1991). The levels of CRH-BP is higher than the levels of 
CRH until approximately 20 days before spontaneous term delivery 
when the concentration of CRH-BP starts to fall and the placental CRH 
levels increase exponentially until delivery ^V[cLean et al 1995). Li other 
words, there is an inverse relationship between CRH and CRH-BP at 
near term. 
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ILA.3.d. Association with human parturition 
The role of placental CRH in normal pregnancy is still undefined. 
However, it may play an important role in the initiation of human 
parturition. There are several evidence to support this. CRH receptors 
are present in the myometrium ^HilUiouse et al 1993) and fetal 
membranes (Petraglia et al 1990). Corticotrophin-releasing hormone 
stimulates human decidua and amnion in vitro to release prostaglandins 
(Jones et al 1989) and a positive effect of protaglandins on placental 
CRH production was also noted (Petraglia et al 1987). Li addition，CRH 
has been shown to synergise with oxytocin to induce myometrial 
contration both in vitro (Quartero et al 1989) and in vivo (McLeanet al 
1994). Corticotrophin-releasing hormone is also secreted into amniotic 
fluid and fetal circulation and one of its possible roles is to stimulate 
the fetal pituitary-adrenal axis to increase fetal adrenal glucocorticoids 
secretion, promoting fetal organ maturation (Challis et al 1989). The 
surge in fetal glucocorticoids at term reflects a maturing HPA and is of 
fundamental importance in preparing the fetal lungs for life outside 
uterus. Glucocorticoids have also been shown to up-regulate the release 
of CRH from placental cells (Robinson et al 1988). The falling of 
levels of CRH binding protein about 20 days before spontaneous labour 
and the exponential increase in bioavailability of CRH just prior to 
spontaneous labour described above also suggest that CRH has a major 
role in the initiation of human parturition. 
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ILA.3.e.Association with preterm delivery and other abnormal pregnancy 
outcomes 
Both cross-sectional and longitudinal studies have reported that 
elevated matemal plasma CRH levels are associated with preterm 
delivery (Wolfe et al 1988, Warren et al 1992). The patterns of plasma 
CRH that are associated with aberrant timing of delivery, both early 
and late, are established by the second trimester and persist throughout 
gestation ^VLcLean et al 1995). These data demonstrate the existence of 
a longitudinal process in the placenta that is established early in 
pregnancy and which influences the subsequent timing of delivery. 
The CRH levels have been reported to be elevated in pregnancy 
complicated with hypertension (Wolfe et al 1988; Perkins et al 1995) 
and it has also been shown that the CRH values at aU stages of 
pregnancy were significantly elevated in patients with pregnancy induced 
hypertension OPM)，regardless of the severity of the disease. The exact 
mechanism is unknown and one of the proposed reason is that CRH 
acts as a peripheral vasodilator in human pregnancy and that the 
exagerated production of CRH in pregnancies complicated by P H may 
be a compensatory mechanism designed to overcome the vascular 
insufficiency associated with this condition (Perkins and Linton 1995). 
Li 1993, Goland et al found elevated umbilical cord plasma CRH 
in growth retarded fetuses and proposed that placental CRH production 
is stimulated in conditions of chronic stress and may modulate fetal 
pituitary adrenal function in high risk pregnancies. 
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The CRH levels in twin prgnancies are significantly higher than 
those in singleton pregnancies at each stage of gestation except at 30-40 
weeks. OSfisbet et al. 1981). Diabetic patients have an increased perinatal 
and neonatal mortality and morbidity due to antenatal complications but 
this was not reflected in the CRH levels which are not significantly 




Fetal alpha-fetoprotein (AFP) was first discovered in fetal serum 
in 1956 (Bergstrand and Czar). It is a specific glycoprotein and the 
molecular weight is 68,000 daltons. to human pregnancy, it is 
synthesized initially in the fetal yo\k sac and subsequently in the fetal 
liver (Gitlin 1975). It is released into the blood stream together with the 
closely related protein, albumin. The physiological function of AFP may 
be as a carrier of essential fatty acids to certain developing cells and as 
a possible inmiunosuppressor, but AFP has been considered to be the 
main fetal plasma protein during early pregnancy. The concentration of 
AFP in fetal serum increases rapidly to a peak level of approximately 
30gA at 12 to 13 weeks of gestation (Gitlin and Boseman 1966) and 
gradually decreases towards term to a concentration of approximately 50 
mg/1 in cord blood. The fetal alpha fetoprotein declines continuously 
during the first year of life but do not reach zero. 
During pregnancy alpha fetoprotein passes into the amniotic fluid 
and also across the placenta, so that the concentration of alpha 
fetoprotein in matemal serum increases until 28-32 weeks of gestation 
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and then rise slowly until late in pregnancy. There is different 
concentration of alpha fetoprotein among fetal serum, amniotic fluid and 
matemal serum. The amniotic fluid alpha fetoprotein reaches its peak 
concentration of around 20mg>l during 13 gestational weeks and is 
approximately 150 to 200 times less than that of fetal serum 
concentration (Crandall et al 1987 ； Drugan et al 1988 ； Elejalde et al 
1990 ； Palomaki et al 1993).The fetal serum AFP origin from the fetal 
yoUc sac and subsequently in the fetal liver (Gitlin 1975). The AFP in 
the amniotic fluid is mainly released through unkeratinized skin of the 
fetus (Aitken et al 1995). The source of matemal AFP is due to transfer 
across both the amniotic membranes and the placental barrier (Thomas 
et al 1990). 
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ILB.2. Maternal AFP levels in the second trimester 
Unexplained matemal serum AFP elevations are associated with 
placental pathologic conditions at delivery (Salafia et al 1988) and with 
placental abnormalities identified during second-trimester ultrasonographic 
evaluations (Perkes 1982). Li addition, it is also associated with 
increased risks of preterm delivery (Milunsky et al 1989). The rate of 
preterm delivery has been reported to range from 16% to 47% and has 
been shown to be directly correlated with the degree of elevation of 
matemal serum AFP (^obinson 1989). Women with elevated matemal 
serum AFP had a 3.6-fold increase in risk of delivering a preterm 
infant compared with women with normal levels (Gordon et al 1978 ). 
The frequency of preterm delivery was also greater among women with 
placental abnormalities when among women without such abnormalities. 
Li 1977, Wald et al observed that women with matemal serum 
AFP values of >3.0 multiples of the median were 5.8 times more likely 
to deliver before the completion of 37 weeks' gestation as compared 
with women with normal level. Furthermore, they found that elevated 
levels was associated with a mean reduction of gestational age at 
delivery by 2 weeks. 
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Higher levels of matemal serum alpha-fetoprotein (AFP) are also 
associated with fetal anomalies particularly open neural tube defects and 
abdominal wall defects, inaccurate gestational age, twins and fetal death. 
(Burton et al 1983). It has also been reported that fetal growth 
retardation is associated with elevated AFP levels (Corry et al 1984). 
Other studies commented that the low birth weights associated with 
elevated mid-trimester MSAFP were related to higher incidence of 
preterm delivery and may not be related to fetal growth retardation 
fPurdie et al 1983; Richard et al 1992). 
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III. MATERIALS AND METHODS 
IILA. Study population 
This is prospective case-controlled study. Between September 1996 
and September 1997, pregnant Chinese women admitted to the Prince of 
Wales hospital because of spontaneous preterm labour at 24- 36 
completed weeks of gestation were recruited for study. The definition of 
‘labour’ is presence of regular uterine contractions of frequency no less 
than 4 per 20 minutes documented by external tocography or any 
uterine activity with either rupture of membranes or cervical effacement 
by at least 50% or cervical dilatation by 2 cm or more and effacement 
(Canadian Preterm Labour Livestigations Group 1992). ‘Preterm’ is defined 
as before 37 completed weeks of gestation. 
Exclusion criteria are as follows: 
a), patient refusal 
b). multiple pregnancy 
c). uncertainty of gestational age 
d). intra-uterine death 
e). fetal open neural tube defect 
f). existence of other complications apart from preterm labour 
g). patient who had labour suppressed by tocolytics or subsided 
spontaneously 
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A control group was selected from uncomplicated pregnant 
Chinese women at the same gestation attending the outpatient clinic of 
the same hospital for routine antenatal check up. All subjects were 
recruited after consent. Those who developed antenatal complications 
after recruitment are excluded later from this study. 
All the recruited subjects had to have dating ultrasound 
examination before 24 weeks' gestation for confirmation of the 
gestational age. This would minimize the error related to wrong 
gestation. 
24 
IILB. Sample Collection and Analysis 
Ten milliliters of matemal venous blood was collected from the 
antecubital vein after recruitment and put in tubes containing heparin. 
The blood samples were kept in ice and centrifuged at 2200 rpm, 4° C 
immediately after collection. The separated plasma were stored in 
aliquots at -20® c in Lee Hysan Laboratory of the Prince of Wales 
Hospital before they were assayed for CRH and AFP levels. A volume 
of 2 ml of plasma was shipped to the Mothers and Babies Research 
Centre, John Hunter Hospital, Newcastle, Australia for assay of CRH. 
Alpha-fetoprotein (AFP) levels were measured with automated 
Microparticle Enzyme Lranunoassay OMEL\) in the Chemical Pathology 
laboratory of Prince of Wales Hospital. Both the measurement of CRH 
and AFP were conduced by me. 
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IILC.1 CRH radio-immunoassay 
IILC.l,a. Theoretical basis for Radioimmunoassay 
The principle underlying RJA is the reaction between an unknown 
amount of antigen (Ag) and a fixed amount of specific antibody (Ab). 
The antigen and antibody are allowed to react so that they bind 
together at sites of complementary amino acids to form 
Ag-Ab complexes. 
<^ + ^  ^ <Z>h 
Antigen Antibody Ag-Ab Complex 
(Ag) (Ab) 
At equilibrium there is a proportion of Ag bound to Ab 
(Ag-Ab complex) and free (unbound antigen) Ag. The amount of Ag in 
the reaction is reflected by the amount of bound and free Ag. hn the 
RL\, radioactively labelled Ag (Ag*) is added to the Ag + Ab reaction 
to compete with the Ag for binding sites on the Ab to form an Ag*-
Ab complex. 
Ag* +Ag +Ab - ^ ^ Ag-Ab +Ag*-Ab +Ag + Ag* 
A standard curve is made so that samples contain a known 
amount of Ag ( such as CRH ).Radioactively labelled Ag*, known as 
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1 o Si 
tracer (such as I-[Tyr^ ]-CRH ) is added to the sample containing 
known amounts of antigen and antibody. The sample is incubated and 
the antigen and the tracer compete to bind to the specific antibody. The 
Ag/Ab interaction reaches equilibrium. The bound-Ag and the unbound 
Ag are separated by the addition of a second antibody which recognises 
and precipitates the Ag-Ab (or Ag*-Ab ) complex. The percentage of 
the total amount of tracer added which bound to the antibody reflects 
the relative amount of Ag in the sample. Samples with unknown 
amounts of Ag can be treated in the same way as the standard samples 
and the percentage of tracer which is bound to the Ab can be used to 
accurately estimate the Ag concentration in the sample. For an RM to 
be accurate the following criteria are required: a pure and highly 
specific tracer, pure standard, highly specific antibody, optimum 
incubation time, optimum pH, adequate separation method and precision 
equipment and technique (Chard 1987). 
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III.C.l.b. Vycor extraction of maternal plasma samples 
Vycor extraction was used to remove any salts or CRH binding 
protein present in the matemal plasma samples. The vycor extraction 
procedure allowed the adsorption of low molecular weight polypeptides 
(such as CRH, MW= 4376 ) from the matemal plasma to powdered 
vycor (glass Mesh 140, Coming, NSW Aust) which had been activated 
by heating to 600® c for one hour (Chan et al 1988). Larger proteins 
which did not bind to the vycor glass were removed, leaving behind 
small polypeptides which were then eluted from the .glass with acidified 
organic solvent. 
Frozen matemal plasma samples (10 mL) were thawed at room 
temperature. Activated vycor glass (0.3g) was added to the matemal 
plasma samples which were then vortexed and mixed thoroughly by 
rotating end-over-end for 30 minutes at 4® c. The resultant suspension 
was centrifuged (J-6B, Beckman Listruments, Gladesville, Australia ) at 
2000 g for 15 minutes at 4¾ , and the supernatant aspirated to waste. 
Each sample was acidified by the addition of 2 mL 1 M hydrochloric 
acid (Analar grade, BDH chemicals, Australia ) and vortexed. The 
suspension was again centrifuged at 2000 g for 15 minutes at 4 \ and 
the supematants aspirated to waste. To resuspend the pellet and elute 
the vycor-bound hormone, 2 mL of 60% acetone (BDH Chemicals, 
Australia) was added and the suspension was vortexed and rotated end-
over-end for 30 minutes at 4�c. The samples were then centrifuged at 
3500 g for 20 minutes at 4¾ and the supernatant containing small 
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molecular weight polypeptides, such as CRH, were transferred to 
polycarbonate tubes (Techno Plas, Australia) and dried using a speed 
vacuum ( Speed Vac, Savant, Adelaide, Australia). The summarised 
protocol for vycor extraction is shown in the following figure 2. Dried 
extracts were stored at -20^c and CRH levels were determined by 
radioimmunoassay (RiA), as described previously by Chan et al (1988). 
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Figure2: Summarised protocol of vycor extraction of matemal plasma samples. 
Thaw matemal plasma s^p le s at room temperature 
Add 0.15 g vycor glass 
I 
Vortex, rotate for 30 min at 4®c 
I 
Centrifuge at 2000 g for 15 min at 4®c 
+ 
Supernatant aspirated to waste 
I 
Add 2 mL HCL (lM) 
I 
Vortex centrifuge 2000 g for 15 min at 4®c 
； 
Supernatant aspirated to waste 
+ 
Add 2 mL 60% acetone 
Vortex, rotate for 30 min at 4 � c ； 
Centrifuged 3500 g for 20 min at 4° c 
I 
Supernatant transferred to polycarbonate tubes 
I 
Sample dried on speed vacuum, stored -20° c 
CRH concentration determined by RJA 
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IILC.l.c. Standard curve 
A stock of hCRH standard 10 ngy^ mL ( Auspep, Melbourne, 
Australia) was thawed at 4 � c and diluted 1:2 to obtain the highest 
concentration in the standard curve ( 3333.33 pgy^ ml ). Ten serial 
doubling dilutions were made from the highest concentration standard 
(3333.33 pgAnL) to produce a standard curve (6.5-3333.33 pgy^mL). 
200 i^L of each known standard concentration was assayed in triplicate 
with the perfusate samples. Maximum binding of the tracer to the 
antibody without competition from CRH standard was determined for 
each standard curve. Li each assay the maximum binding was 
determined by the first point on the standard curve containing no CRH 
standard, 200 t^L RL\ buffer, 50^iL antibody (Y2B0 1:7000 ), and 50 
HL purified tracer ^^^ I-[Tyr^-CRH (5,000-10,000 cpm). Figure 3 showed 
the standard curve of hCRH. 
The sensitivity of the RL\, that is, the minimal detection limit of 
the assay, was determined to be the maximum binding minus 2 times 
the average standard deviation (SD) of the triplicates for each standard. 
The range ( or upper limit) of the RL\ was determined to be the 
minimum binding (200 M^  RL\ buffer with 3333.33 pg/ml CRH, 50 i^L 
antibody and 50 pL tracer) plus 2 times the average SD. 
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hCRH Standard Curve 
40 ^  —~~»n 
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[hCRH] pg/ml 
Figure 3: The standard curve of hCRH 
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IILC.l.d. Antisera 
The antibody directed to the C-terminus of the hCRH molecule, 
Y2B0 was raised in rabbits and supplied by Dr Phil Lowry. (Reading 
University, U. K.). This hCRH antibody was used in a 1 : 7000 dilution 
for hCRH RL\ of matemal plasma samples. Optimal Y2B0 
concentration (1:7000) was determined from titre tests to give 
approximately 30% in the absence of standard i.e. no standard 
competing with the tracer to bind to the antisera. Antisera (50 ^iL) was 
added to CRH standard samples and matemal plasma samples on day 1 
of the RL\, vortexed and incubated at 4® c. Polyclonal antibodies for 
hCRH were raised in rabbits as an extension of this project. However, 
the polyclonal antibodies raised were not used in the RJA carried out 
for this thesis. 
r u 丄 c n z n ~ ] 
J 十 y ~ ^ LL 
hCRH molecule Y2BO Ag-Ab 
(Antigen) (Antibody) (Complex) 
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IILC.l.e. Tracer 
Radioactive iodine ( ^ I ) was incorporated into a synthetic CRH 
molecule which has a tyrosine residue conjugated to the N-terminus. 
[ T y f ]-CRH. The tyrosine residue provides the target for iodination. The 
iodination method used was based on a modified method to that used 
by Greenwood et al, (1963 ) which is routinely used in the Endocrine 
research laboratory located at the John Hunter Hospital, Newcastle. The 
reaction mixture consists of 5 i^g [Tyf ]-CRH ^Peninsula, Bahnont, USA) 
in 20 i^L of 0.5 M sodium phosphate buffer, pH 7.4 (BDH Chemicals, 
Australia), 10 i^L chloramine-T (0.5 mgy^ mL dH2 0) (BDH Chemicals, 
Australia) and 5 p,L (0.5 mCi) Na^ ^^  I (Australian Radioisotopes, Australia) 
vortexed and then incubated in polystyrene tubes (Techno-Plas, South 
Australia) for 40 sec. The reaction was stopped with 20^L of 0.5 
mg/mL sodium metabisulphite and the solution diluted with 0.5 mL 
0.1% Trifluoroacetic acid (TFA) 
(BDH Laboratory Services, Aust), 0.1% BSA, 0.1% Polypep (Sigma, 
USA). The solution was transferred to an activated octadecylsilica 
minicolumn (Cig -Sep Pak, Millipore, Australia ) which had been 
previously activated by cycling throough the following solutions 5 mL 
of 80% propanol containing 1% TFA, 5 mL of 1% TFA, 1 mL 1% 
TFA containing 0.1% Polypep, 5 mL of 1% TFA, 10 mL 80% 
propanol containing 1% TFA 10 mL 1% TFA (Chan et al 1988). 
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The iodinated antigen was eluted from the Cig -Sep Pak cartridge using 
the following washes of propanol (BDH Laboratory Services, Australia ) 
in 1% TFA (BDH Laboratory Services ,Australia) [%propanol]: 0，5，10， 
15, 20, 21，22, 23，24, 25, 26, 27, 28, 29，30, 40 and 80. The fractions from 
the Ci8 -Sep Pak cartridge were counted at a fixed distance of 0.40 m 
from a portable gamma counter (scintillation meter type 5.40, mini-
instruments, Essex, England). 
Unincorporated iodine was retained by the octadecylsilica particles 
in the Cig -Sep Pak cartridge and was eluted in the fraction with the 
aqueous solvent，1% TFA. Radioactivity detected in fractions of higher 
solvent strengths represented � i that had been incorporated into the 
amino acids of the CRH peptide i.e. ^^^ I-Tyr^ -CRH. Peak fractions of 2 
mL (usually fractions eluted with 26-28% propanol) were dried over 
night in a speed vacuum. Peak fractions were tested for their binding to 
antisera. (Y2B0 1 : 7000) overnight. The fraction with the highest 
binding (i.e. approximately 30% ) was purified using High Pressure 
Liquid Chromatograhy ^HPLC). 
i 2 5 R + < - T y r ^ - C R H ^ ^ ^ ^ I ^ y r ^ - C R H 
Radioactive Tyrosine Tracer 
iodine CRH molecule 
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IILC.l.f. HPLC Tracer Purification 
The tracer was purified using HPLC purification. The dried 
fraction with highest binding was reconstiured in 200 i^L 0.1% TFA 
(1000 mL dH2O, 1 mL TFA ^ffLC grade，BDH) and 0.1% triton X-
100 (O.lmL Triton X-100 (Sigma Chemical Company, St Louis, M. 0., 
USA), 100 mL H2O, (filtered using Millipore GVWP 0.22 ^M filter) 
and dissolved by rotating for 1 hour at room temperature. The tracer 
was loaded onto a Cig Columns, Applied Biosystems) as a bolus 
injection of 200 ^L and eluted using a step gradient from 0.1% 
TFA,(filtered using Millipore GVWP 0.22 i^L filter) to 0.07% TFA/70% 
acetonitrile (made from 1400 mL acetonitrile, (BDH Laboratory 
Services), 1.4 mL TFA and 600 mL dH2O which was filtered using 
Millipore GVWP 0.22 ^L filter) at a constant flow rate of 1 mL/min 
as described in Table 1. The activity in each fraction was measured 
using a portable gamma counter at a fixed distance of 0.05 m. 
Fractions with the highest counts (fraction 22-25) had 0.1% BSA added 
and were stored at 4°c. The binding of each of the peak fractions to 
antisera was tested and the fraction which gave approximately 30% 
binding with Y2B0 1:7000) was used. 
On day 2 of the mA procedure, 50 jnL of CRH tracer (5,000-
10,000 cpm/50 fiL) was added to samples, vortexed and incubated at 
4"c. 
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Table 1. Change in concentration of acetonitrile in the 
elution buffer for HPLC purification of CRH tracer. 
The elution buffer changes over time from 0.1% TFA 
to 70% acetonitrile 0.1% TFA. 








IILC.l.g. Separation of bound from unbound CRH: 
Second antibody 
Antibody-bound CRH and unbound CRH were separated using a 
solid phase second antibody. Donkey anti-rabbit antibody (Sac-Cel, 
Wellcome Diagnostics, Concord, N.S.W, Australia) (50 ^L) was added 
on day 4 of the RJA and incubated at room temperature for 30 min. 
The RL\ reaction mixture was diluted with 500 juL dH2O and 
centrifuged at 4000 g for 10 min at 4 � c . The supernatant was aspirated 
to waste and the pellet counted on a gamma counter. 
(Crystal, United Technologies, Packard, USA). 
K ^ 
i25HTyr�r t l + & + a = i 2 5 l - [ T y r � j j ; g 十 [ ； ^ 
(Tracer) (hCRH) (Y2B0, first antibody) (*Ag-Abl。） （Ag-Abl。） 
*Ag Ag Ab r 
i25l-[TyrO] ''^I-[Tyn '''l-[Tyr"] 
ri"h m LT p 4 i _ _ p_L, „ _ 
] + D + Q£| J ! ^ ] + • + ] + 3 
^ 丁 V 丁 ‘ ~ ‘ ^ ~ t T t T L ^ T L ^ 
(*Ag-Abl� ) ( Ag-Abl� ) ( Ab 2 � ) Y T P H 
(*Ag-Abr -Ab2" )=Y (Ag-Abl�-Ab2�)=T 
(*Ag-Abl�y=? ( Ag-Abr )=H 
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IILCl.h.CRH radioimmunoassay procedure 
A standard curve was prepared from synthetic hCRH standard (1-
41) (0-3333.33 pg/mL) hCRH). Each concentration of standard was 
prepared in duplicate (200 ^L). For RL\ 200 ^L of reconstituted vycor 
extracted matemal plasma samples were diluted three times and each 
dilution prepared in duplicate. Antiserum (Y2B0 1:700) (50 i^L) was 
added (except to total tubes containing 50 i^L tracer only) to the 
samples and vortexed and placed in a cold-room ovemight at 4® C. 
After 24 hours, 50 i^L of tracer (5,000-10,000 cpmy^ 50 pL) was added to 
all tubes and the tubes were vortexed. Samples were placed in a cold-
room at 4 � C for a ftuther 48 hours. The second antibody (Sac-Cel 
donkey anti-rabbit) (50 ^L) was added to samples (except to total tubes 
containing 50 i^L tracer only), vorterxed and left at room temperature 
for 30 min. Distilled water (500 \xL) was then added and the samples 
centrifuged at 4000 g for 10 min at 4® C. Supematants containing 
unbound CRH ad tracer were aspirated to waste. The pellets were 
counted using a gamma counter to measure the amount of tracer bound 
to antibody. The amount of CRH in samples was extrapolated from the 
standard curve. 
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IILC.2. CRH Reagents 
Assay Buffer: 
O.lM sodium phosphate 7 mL of 2M NaP stock 
0.25% [w/v] bovine serum albumen 0.35g BSA 
0.01% [v/v] B-mercaptoethanol 0.14 mL B-HSEtOH 
0.02% [w/v] sodium azide 0.028g Na 
phenol red small amount 
pH 7.4 made up to 140 mL with deioised H2O 
Standard : 
A standard curve is prepared from the synthetic hCRH stock standard 
(0-3333.33 pgy^ mL hCRH). Each concentration of the standard is assayed 
in triplicate (200 i^Lx3). Synthetic human, rat Corticotrophin Releasing 
Factor 1- 41 (h,r CRH) from 
a) Peninsula Labs, Code #8561. in the past 
b) Auspep Code #2028, in the more recent past 
c) Macromolecular Resources, Colorado, custom synthesized, used. 
1® Antiserum : 
The antiserum is 164.4 sheep anti-human CRH .It has been used at a 
predilution of 1/19000. 
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Samples: 
Dried Vycor extracted plasma samples (including spiked and unspiked 
controls) are reconstituted in 0.5 mL RL\ buffer, vortexed and rotated 
at 4° C for 30 min. The pH of the samples is adjusted to pH 7.4 if 
necessary using 0.2M NaOH or O.lM HCL. Centrifuge at 2,500 rpm at 
4°C for 10 min. Duplicates are assayed. Due to the exponential rise in 
CRH, the sample size assayed depends on gestational age . <26 weeks 
200 i^L x2 >27 weeks 100 i^L >36 weeks 50 i^L x2 
Tracer: 
Radioactive iodine (^^¾ was incorporated into a synthetic CRH 
molecule which has a tyrosine residue conjugated to the N-terminus, 
[Tyr�]-CRH. 
r 
SET-PAK Ci8 Cartridge : 
It can be performed in water or in the most polar aqueous organic 
solvent mixture possible. The polar compounds elute before non-polar 
compounds .The iodinated antigen is eluted and the unincorporated 
iodine is retained by the octadecylsilica particles in the Cig-Sep Pak 
cartridge using the fraction with the aqueous solvent 1% TFA. 
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IILC.3. Estimation of CRH extraction recovery. 
Non-pregnant plasma were spiked with a known amout of 
standard CRH (250 pg/mL). The samples were vycor-extracted, dried 
and assayed in the same way as the other non-spiked samples. 
Percentage recovery of spiked CRH was averaged from the extractions. 
Percent recovery was calculated by: 
Percentage recoverv = [CRH spiked plasma] - [unspiked plasma] xlOO 
[CRH added] 
Spike non-pregnant plasma with 250 pg/mL CRH. 
Unspiked plasma=21.77+6.07 pgy^ mL (n=5) 
Spiked plasma=247.75±28.98 pg/mL (n=9) 
Percentage recovery = 247,75 - 21.77x100 =90.39% 
250 
The concentrations of CRH measured in matemal plasma samples in 
this are expressed as absolute values pg/mL/g measured by RJA, i.e. 
results have not been corrected for vycor extraction recovery, 
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IILC.4.Sample Dilution 
Dilution = assay 0 ^ ^ ) dependent on the volume of sample, 
e.g. if use 200 ^1 sample then: 
(a) 200 fil sample + 50 jxl As + 50 ^1 Tracer = final volume 300 i^l 
dilution =200/300 = 1.5 
(b) 100 pl sample 
dilution =100/3W) = 3 
(c) 50 jid sample 
dilution = 20/300 = 6 
Concentration factor: CF 
CF = volume of sample / volume the sample is reconstructed 
e.g. if 1 ml of sample is extracted and dried and then reconstructed in 
0.5 i^l Buffer. CF = 1/0.5 二 2 
Multiplication factor: 
M F = X dilution / concentration 
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III.D. AFP- Microparticle Enzyme Immunoassay 
III.D.1. Principles 
A capture molecule coats with submicron microparticles (0.47 t^m 
in diameter) specific for the anaIyte being measured. A suspension of 
microparticles will be used more than polystyrene bead or coated-tube 
soled phase, because it provides greater effective surface area. Because 
of the increase in surface and shortening of the diffusion distance 
between analyte and capture molecules, the surface of microparticle 
accelerated analyte binding and attainment of equilibrium, in order to 
diminish the incubation time. The reactants binds irreversibly to the 
glass fibre matrix in the reaction cell. ^Flore et al., 1988; Keller et al., 
1991; L:nx System Operation Manual, Abbot Laboratories) 
The reactants of MEL4 assays are microparticles coated with a 
capture molecule which is antigen, antibody or analyte specific moiety, 
aUcaline phosphatase-labelled conjugate, flurogenic substrate that is 4-
methylumbelliferyl phosphate (4-MUP) and reaction cell which has a 
glass fibre matrix to which the immune complex binds. 
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III.D.2. Reaction Process 
The reaction process of MElA assay is showed in Figure 4 (Lm 
System Operation Manual, Abbot Laboratories). Samples and 
microparticles were incubated with the reaction cell The samples of 
alpha-fetoprotein bound to the microparticles to form an immune 
complex during the incubation period. The glass fibre matrix reacted to 
an aliquot of the immune complex. Then, the immune complex bound 
irreversibly to the glass fibre matrix. The unbound materials of matrix 
was removed by washing and the immune complex was retained by the 
glass fibre. At that time, aUcaline phosphatase-labelIed conjugate was 
added to the matrix to form an "antibody-analyte-conjugate sandwich". 
The matrix was washed once again. A fluorogenic substrate (4-MUP) 
was added. The inorganic phosphatase and fluorescent 4-
methylumbelliferone (4-MU) were hydrolyzed from fluorogenic substrate 
(4-MUP) under catalyzing by aUcaline phosphatase conjugate. Finally, the 
MEL\ optical assembly measured the intensity of fluorescent light 
produced by 4-MU which is proportional to the concentration of the 
analyte. 
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Figure4: Reaction Process of Microparticle Enzyme Immunoassay. 
The following is an illustration of the typical MEL\ reaction process: 
• + : - 《 乂 . 
Anti-Analyte Microparticle Sample Antibody-Antigen Complex 
v ^ 
十 o ^ — � ？ 
C ^ � 
Anti-Analyte-Specific Antibody-Antigen Antibody Complex 
AUc Phos Conjugate Captured by the MEL\ Reaction Cell 
Glass Fiber Matrix 
+ @ ) - � " ^ + / ? \ -
4-Methyliunbelliferyl Antibody-Antigen Methylumbelliferone 
Phosphate (MUP) Antibody Complex (MU) is fluorescent 
Rate ofMU production 
is Measured. 
MELV schematic reaction sequence 
Source: Adapted from JMX System Operation Manual, Abbot Laboratories 
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IILD.3. MEIA Optical Assembly 
A front-surface flurometer was used in the MELA, optical 
assembly. The mercury arc lamp generated excitation energy which 
filtered to 365 rnn to excite 4-MU molecules. 4-MU was excited to 
emits light at 448 nm. The 448 nm light generated was measured. The 
intensity of 448 nm light was proportional to the concentration of the 
analyte. Known concentration of samples were measured to plot a 
calibration curve which is stored in the M x system. As a result, 
unknown concentration can be calculated. 
III.D.4. Operation 
Firstly, the appropriate assay software module is put in place by 
the operator ,and then loads 24 reactions cells in a carousel. A 
minimum of 150 |il of specimen, control sample or calibrator is added 
to the sample well of the reaction cell. Opening the access door, then 
put the carousel into the analyzer and the reagent pack is placed into 
the reagent block. After having closed the door, one can start the assay 
by pressing the "run" button. Then, all steps are fully automated. 
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III.D.5. AFP Reagents 
The reagents include JMx AFP reagent pack (No. 2257-20), EVbc 
AFP mode 1 calibrator, M x AFP calibrators (No. 2257-01), M x 
controls (No. 2257-10) and M x AFP specimen diluent Osfo. 2257-50). 
The reagent pack QSTo. 2257-20) contains four bottles including: 
1. 1 bottle (4.5 ml) anti-AFP (mouse, monoclonal) coated 
microparticles in buffer with protein stabilizers. 
Preservative: sodium azide. 
2. 1 bottle (6.0 ml) anti-AFP (mouse, monoclonal): 
aUcaline phosphatase conjugate in buffer with protein 
stabilizers. Preservatives: sodium azide and 
antimicrobial agents. 
3. 1 bottle (10 ml) 4-MUP, 1.2 mM in buffer. Preservative: 
sodium azide. 
4. 1 bottle (16 ml) specimen diluent, buffered calf serum. 
Preservatives: sodium azide and antimicrobial agents. 
There is 1 bottle (4ml) M x AFP (human) mode 1 calibrator 
(AFP prepared in buffered calf serum). Concentration: 50 ngy^ ml. 
Preservatives: sodium azide and antimicrobial agents. 
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The M x AFP (human calibrators (No. 2257-01) include 6 bottle 
(4 ml each) of concentrations of 0, 15, 50, 100，200, 350, ng/ ml. 
Preservatives: sodium azide and antimicrobial agents. 
There are 3 bottles (4 ml each) of DVbc AFP (human) controls 
_2257-01) , low (15-25 ng/ml), medium (64-96 ngAnl) and high 
controls (140-210 ngy^ ml). Preservatives: sodium and antimicrobial 
agents. 
There is 1 bottle (lOOml) JMx AFP specimen diluent (No. 2257-
50)， buffered calf serum. Preservatives: sodium azide and 
antimicrobial agents. 
III.D.6. Sample Dilution 
When the result was greater than 350 ng/ml, the specimen 
should be diluted 3-fold with JMx AFP specimen diluent 0STo.2257-




III.D.7. Inter-assay and Intra-assay Variation 
For evaluation of the intra-assay variation, the same sample was 
assayed 10 times within the same assay. And also, for evaluation of 
inter-assays. The mean and the standard deviation (SD) of optical 
density (OD) of both high and low range samples were calculated. The 
co-efficients of variation (CV) within and between assays were 
calculated according to the formula CV=SD (OD) / mean (OD). The 
results of the intra-assay and inter-assay variation of CRH and AFP 
assay are shown in Table 2 and 3 respectively. 
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Table. 2 :Inter- and Intra-assay Variation of CRH Assay 
Inter-assay intra-assay 
OD(LC) OD(HC) OD(LC) OD(HC) 
~ ~ r M 5 377.39 TSM 307.868 
~ ~ ~ 1 ^ 345.29 ^ r E 304.798 
~ ~ K ^ l 362.60 K I b 324 .21~ 
~ ~ K f l 356.08 r ^ 330.34~~~ 
~ ~ K ^ 345.65 1 ^ 313.47~~" 
~ ~ ~ r m 363.48 TK^ 339.608 
~ ~ r ^ 387.51 i ^ 304.982 
~ ~ K n 405.30 f ^ 3 3 9 . 0 3 “ 
~~~r735 392.80 K I o 312.02~~~ 
~ ~ " K ^ 347.77 f ^ 338.72""" 
Mean i ^ 368.39 K n 32i.50~~~ 
S.D 0 9 2L32 0 ^ i 4 ^ ~ ~ 
C.V 7.83% 5.79% 5 ^ 4.53% 
LC= Lowest concentration. 
HC= Highest concentration. 
OD= optical density 
SD= standard deviation 
CV= co-efficients of variation 
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Table. 3 :Inter- and Intra-assay Variation of AFP Assay 
Inter-assay intra-assay 
OD(LC) OD(HC) OD(LC) OD(HC) 
~ ~ ~ 1 ^ 2 ^ 1 ^ 3 ^ 
~ ~ " f m 2 ^ 1 ^ 3 ^ 
~ ~ " U ^ 2 m 1 ^ 3 ^ 
~~n7^6 2 ^ 1 ^ 3 ^ 
~ ~ " 1 ^ 2 m ] ^ 3 4 ^ 
~ ~ 1 ^ 3 ^ i ^ m 9 
~ ~ f ^ 308.5 f ^ 387.2 
" ^ ^ r ^ 311.4 r ^ ^ 
~ ~ ~ 1 ^ 3 ^ n ^ 391.9 
~~~143.2 315.8 V ^ l 3 ^ 
Mean i ^ 2 m 1 ^ 3 ^ 
S.D iT2 1^ ^ ^ 
C.V 8 ^ J ^ 4^^ 9^ 0%~~~ 
LC= Lowest concentration. 
HC= Highest concentration. 
OD= optical density 
SD= standard deviation 
CV= co-efficients of variation 
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IILE. Data Handling 
The biochemical results and clinical information were analysed by 
the 586 personal computer using statistical Package for the Social 
Sciences Version 7.0 (spss Lic,Illinois, U.S.A.) 
IILF. Statistical Analysis 
The demographic data of pregnant subjects were analysed by the 
Chi-square test and Mann-Whitney U test. We use Chi-square test to 
analyse the catagorical data. When the data is continuous data, Mann-
Whitney U test would be used. As each subject in the preterm group 
was matched with a subject from the control group at matched 




From September 1996 to September 1997, 38 pregnant women 
complicated with spontaneous preterm labour between 26-36 weeks of 
gestation were recruited for the study. Eight subjects were later 
excluded as labour was successful suppressed and their pregnancies 
subsequently continued to term . The study group consisted of the 
remaining 30 subjects who had spontaneous preterm delivery between 
26-36 completed weeks of gestation. They did not have other antenatal 
complications apart from preterm delivery. Thirty normal pregnant 
subjects were recruited at the matched gestation from the out-patient 
antenatal clinic in the control group. They were free of any medical 
disease or antenatal complications and all delivered at term. 
i 
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rV.A. Demographic Data 
The dermographic data of the recruited subjects are shown in 
Table 4. There were no significant difference in matemal age, height, 
weight, body mass index, gravidity and parity between the preterm 
group and control group. Other variable such as previous history of 
induced abortion, recurrent spontaneous abortion and preterm delivery, 
history of smoking, marital status, and occupation that involved heavy 
manual work were also found to be of no statistical difference between 
the two groups (p>0.05). 
Table 5 showed the characteristics of the index pregnancies for 
the recruited subjects. There was no statistically significant difference 
between the two groups in percentage of positive culture from high 
vaginal swab and placental swab. The preterm group had a 2 times 
higher incidence of threatened abortion though the difference has not 
reached statistical significance (P=0.058). The mean birth weight was 
found to be significantly lower among the preterm group ^x0.05), 
which was related to the delivery at as earlier gestation. There was no 
difference in the neonatal sex ratio. 
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Table 4 Demographic data of study subjects 
Preterm Group Control Group 
n=30 n=30 P value 
Mean (SD) Mean (SD) 
or (%) or (%) 
Age (Years) 30.1 (6.3) 30.4 (5.4) N ^ 
Marital status 3(10%) 1(3.33%) ^ 
(Single) 
Maternal Height (cm) 155.9 (5.8) 157.2 (5.3) KK 
Maternal Weight (kg) 56.0 (6.9) 54,8 (8.3) KK 
Body Mass 23.1 (3.2) 22.3 (3.7) N ^ 
Index (kg/m^) 
Gravidity 2.17 (1.49) 2.33 (1.30) i ^ 
Parity 1.3(43.33%) 1.7(56.67%) N ^ 
~~Previous preterm 2(6.67%) 0 (0 %) KK 
delivery 
~~Previous induced 5(16.67%) 6(20%) N^^ 
abortion 
Previous recurrent 1(3.33%) 0 (0%) ^ 
spontaneous abortion 
Smoking 2 (6.67%) 1 (3.33%) ^ 
Occupation (Heavy 2(6.67%) 3(10%) ^ 
manual work) 
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Table 5. Characteristics of current pregnancy. 
Preterm Control 
Variable N=30 N=30 p 
Mean Mean 
Or % Or % 
Treatened 14(46.67%) 7(23.33%) 0 . 0 5 8 ~ 
abortion 
Positive culture from 7(23.33%) 2(6.67�/�) ^ 
High vaginal swab 
Positive culture from 3(10%) 0 0 ^ 
Placental swab 
Neonatal Birth Weight 1.97(0.56) 3.25(0.35) <0.05~~ 
(kg) 
Neonatal sex 17(56.67%) 16(53.33%) ^ 
(male) 
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IV.B. CRH Levels 
IV,B.1. CRH levels increase as gestation advances 
Figure 5 showed log-linear regression line of matemal plasma 
CRH concentration against the gestation at blood sampling in normal 
pregnancies. The matemal plasma CRH levels increased from 32.24 
pmoVml at 26 completed gestational week to 779.98 pmoL^ml at 36 
completed gestational week. A significant positive correlation was found 
between the CRH concentrations and gestation at blood sampling 
(r=0.422; P<0.01). This fmding was in agreement with those reported in 
the literature. 
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IV.B.2 The association between the plasma CRH 
levels and the time to delivery. 
Figure 6 demonstrated the association between the plasma CRH levels 
and the time to delivery after recruitment. A significant negative 
correlation was noted (r= - 0.44, p=0.01). 
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IV.B.3. Elevated CRH levels among the preterm 
group 
Figure 7 showed the log-linear regression lines of matemal plasma 
CRH levels for the preterm and control groups respectively. Both lines were 
parallel (r= and for preterm and term groups respectively) and the CRH 
levels of the preterm group were significantly higher than those of the 
control group O^ilcoxon test, P=0.008). 
Figure 7: The distribution of matemal plasma CRH in preterm 
pregnancies and comparing to the normal pregnancies. 
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IV.B.4. CRH levels and history of threatened 
abortion. 
Li the preterm group, there were 12 patients having a history of 
threatened abortion where there were only 7 patients who had a history 
of threatened abortion in the control group. Though it does not reach 
statistical significance, the difference in the history of threatened 
abortion between the preterm and control group does raise a concem 
whether a history of threatened abortion may be a confounding factor 
for the CRH levels. A comparison of CRH levels is made between 
those with history of threatened abortion and those without in the 
preterm group by Mann-Whitney U test. The two groups were not 
different in terms of gestation at blood taking. The median CRH levels 
for those who had history of threatened abortion and those who had not 
were 206.45 pmol/L (IQR: 104.74-689.29) and 343.73 (IQR: 191.05-
725.45) respectively. There is no statistical difference in the CRH levels 
between the two groups OP=0,067). Hence, the increase in CRH among 
the preterm group when compared to of the control is not related to 
the higher incidence of threatened abortion among them. 
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IV.C. AFP levels 
IV.C.1. AFP levels and gestational age 
The Log-linear regression line of the matemal plasma alpha-
fetoprotein (AFP) concentration against the gestation at blood sampling 
in the control group were shown in Figure 8. There was no statistically 
significant correlation between alpha-fetoprotein concentration and 
gestational age and (r=0.111 ； P>0.05). 
Figure 8. The distribution of matemal plasma alpha-fetoprotein levels 
and gestational age. 
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IV.C. 1. AFP levels and preterm labour 
As there was no significant correlation between AFP levels and 
gestational at sampling, the AFP levels for each groups of subjects 
were presented by blox-plot. (Figure 9). The median AFP levels of the 
preterm and control groups were 242.16 pgytol (IQR: 174.67-331.32) 
and 210.19 pg/ml (IQR:155.35-279.86). There were no significant 
difference in the AFP levels between the two groups OP^0.336, 
Wilcoxon test). 
Figure 9. The distribution of AFP levels in preterm group and 
the term group. 
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This project showed that matemal plasma CRH but not AFP 
levels were elevated in women who had spontaneous preterm delivery. 
This positive correlation between plasma CRH levels and spontaneous 
preterm delivery has not been demonstrated before in ethnically Chinese 
population. 
V.A. Importance of Dating 
The CRH and AFP levels are gestation dependent and it is very 
important to have the gestational age of the recruited subjects confirmed 
by dating scan. Dating is also important to define those subjects 
presenting with preterm labour. Gestational age calculated from last 
menstrual period is known to contain error and the use of early 
ultrasound examination for dating minimizes the error of estimation of 
gestational length to within 7 days (Reece et al 1994). It is the reason 
why one of the criteria for recruitment in this study was that all the 
recruited subjects must have confirmed gestational age by early 
ultrasound scan before 24 weeks. 
V.B. Diagnosis of preterm labour 
The diagnosis of preterm labour is very difficult and accurate 
diagnosis can only be made retrospectively (Lockwood CJ 1995). 
Prospective study encounters practical difficulty in identifying the 
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suitable subjects. Even with regular uterine contractions, some of the 
patients may not go into preterm labour and delivery. The inclusion of 
subjects with false labour may dilute the sample and positive results 
may become insignificant. Lti order to minimize the possibility of 
subjects with false labour, only those presenting with spontaneous 
preterm labour resulting in preterm delivery were included. Others 
subjects with regular uterine contractions, whether or not tocolytic 
therapy was instituted, but did not deliver in preterm gestation were 
excluded based on the ground that false labour could not be excluded 
in these cases. 
V. C.1. CRH and labour 
There is considerable evidence to suggest that CRH may have an 
important role in the initiation of human parturition. Corticotrophin-
releasing hormone receptors are found in the myometrium ^Iillhouse et 
al 1993) and fetal membranes (Petraglia et al 1990). The releasing of 
prostaglandins from human decidua and amnion in vitro (Jones et al 
1989) is stimulated by the CRH and CRH also potentiates the action of 
oxytocin in inducing myometrial contraction in vitro (Quartero et al 
1989) and in vivo 0v4cLean et al 1994). Corticotrophin-releasing 
hormone is capable of stimulating the fetal pituitary-adrenal axis to 
increase fetal adrenal glucocorticoid secretion in the amniotic fluid and 
fetal circulation (Challis et al 1989). Prostaglandins and glucocorticoids 
whose synthesis are induced by CRH, in tum stimulate further placental 
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CRH secretion (^obinson et al 1988), creating positive feedback loops 
in the matemal，fetal and amniotic compartments which may promote 
parturition and drive the onset of labour (Challis et al 1989). 
Although the mechanism of preterm labour remains poorly 
understood, our findings of higher CRH levels amongst preterm group 
suggest that CRH also carries a role in the preterm labour. It may be 
true that the mechanism of preterm labour is the same as that of a 
term labour. Measurement of CRH in patients presenting with regular 
uterine contractions in preterm may be of clinical significance as high 
levels are associated with preterm delivery. It is unclear from my project 
as yet whether those having labour suppressed by tocolysis have lower 
CRH levels when compared to those whose labour cannot be suppressed 
because the former group was not analysed. A recent paper (Korebrits 
et al 1998) did address this question and has shown that the matemal 
plasma CRH levels is elevated between 28-36 weeks of gestation in 
women with threatened preterm labour destined to give birth within 24 
hours of admission. This further supports the suggestion that CRH plays 
an important role in human parturition. 
V.C.2. CRH and Infection 
Preterm labour could be caused by intrauterine infection. One 
concem is that infection with associate cytokine release may stimulate 
placental CRH production. It is therefore important to know whether 
there is an association between CRH and evidence of infection. The data 
in this project did not allow a concrete conclusion to be drawn because 
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there were only 3 subjects in the preterm group who showed positive 
culture from placental swab. The evidence from other published studies 
failed to fmd a positive relationship between CRH levels and infection 
(Warren et al 1992, Korebrits et al 1998). This suggests that in women 
with chorioamnionitis, there are other mechanism that initiates labour. 
V.CJ. Diurnal rhythm of CRH 
One concem in this study is that blood sampling took place 
during different time of the day. There is potentially a source of biases. 
However, it is not practical and not possible to restrict the blood taking 
time as preterm labour presents at any time of the day. Also, blood 
sampling has to be performed before the institution of steroids and 
tocolytic therapy to minimise the effects of these drug on the CRH 
levels. The CRH levels have been shown to be elevated after the 
adminstration of corticosteroids (Korebrits et al 1998). The effects of 
tocolytic therapy on CRH levels have not been documented in the 
literature but according to personal communication with researchers in 
Mothers and Bablies Research Centre, Newcastle University, Australia, P-
agonist does not affect the CRH levels. From the literature, it has been 
shown that there is no diumal variation in matemal plasma CRH 
concentrations OPetraglia et al 1994; Magiakou et al 1996) and hence the 
difference in CRH levels between the preterm and control groups cannot 
be accounted by the diumal variation. 
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V.C.4, Laboratory assays of CRH 
Extracted plasma was used for measuring CRH level in this 
study. Vycor glass was used for extraction. It binds peptides, so CRH 
and the CRH-binding protein (CRH-BP) complex are both bound. The 
step of water wash removes all the water soluble substances not bound 
to the glass. Then at the acid wash step, the CRH is dissociated from 
its binding protein and then acetone (the organic phase) elutes the CRH 
off the glass. Its total CRH that we measured but the CRHBP is 
removed before assay. Previous study of measuring CRH levels using 
the two-site immunoradiometric assay (Linton et al 1988) instead of 
using extracted plasma has the limitation due to the interference in the 
assay by the CRH-BP, which competes with the CRH anti-serum for 
both the CRH and tracer. The CRH-BP levels are highly variable in 
different individuals (Linton et al 1993) and this contributes to the large 
interpatient variation in the CRH levels (Perkins and Linton et al 1995). 
Extraction removes the confounding effects of CRH-BP. The CRH levels 
should therefore always be assayed in extracted plasma. 
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V.D. AFP and labour 
Although elevations of MSAFP in the second trimester is 
associated with preterm labour, the sensitivity is low as only 13 to 15% 
of preterm delivery are associated with elevated MSAFP levels (Smith 
et al 1980) and most women delivering prematurely had normal MSAFP 
levels. 
The result of the present study showed that there were no 
significant difference in the MPAFP levels between the preterm group 
and the normal pregnancy between 26-36 weeks of gestation. 
Conflicting results have been reported by other workers, to 1991， 
Simpson et al found that MSAFP levels were predictive of preterm 
delivery between 15 and 20 weeks and 24 and 36 weeks. They showed 
that MSAFP elevations in the second and third trimester were usually 
independent of each other. However, O'Brien et al (1990) recruited 175 
pregnant women who were considered at high risk of preterm delivery 
between 27-32 weeks and their MSAFP were measured to test if they 
were predictive of preterm labour. They failed to find the positive 
relationship between the MSAFP and preterm labour. Our study was 
carried out in a different way in that 30 pregnant women were 
recruited during early labour between 26-36 weeks of gestation and 
their AFP levels were compared with the control group at matemal 
gestation. Our result also did not support that AFP was increased in 
spontaneous preterm delivery. The reason for an association between 
elevated AFP levels and preterm delivery in the second trimester but 
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not in the third trimester is unclear. It has been postulated that it may be 
due to a large variability in normal population during the third trimester 
(Tlodeck et al 1976). Another possibility is that AFP does not play any 
role in preterm labour. 
Meena et al (1995) compared the MSAFP levels of labouring and 
non-labouring patients at term and found that they were not statistically 
different. The lack of association of MSAFP and labour suggests that 
AFP may not play any role in spontaneous labour. 
My result failed to show that the AFP levels in matemal plasma 
are different in women with spontaneous preterm delivery when 
compared with normal population The failure of finding a relationship 
between the MSAFP level and spontaneous preterm delivery suggests 
that AFP may not have a role in the process of preterm labour. 
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